Bio-Techne Corp reports results for the quarter ended June 30 - Earnings Summary

• Bio-Techne Corp TECH reported quarterly adjusted earnings of 53 cents​​ per share for the quarter ended June 30, higher than the same quarter last year, when the company reported EPS of 49 cents. The mean expectation of sixteen analysts for the quarter was for earnings of 50 cents per share. Wall Street expected results to range from 47 cents to 52 cents per share.

• Revenue rose 3.5% to $316.96 million from a year ago; analysts expected $315.60 million.

• Bio-Techne Corp's reported EPS for the quarter was a loss of 11 cents​.

• The company reported a quarterly loss of $17.68 million.

• Bio-Techne Corp shares had risen by 6.2% this quarter and lost 24.1% so far this year.

FORECAST CHANGES

• The mean earnings estimate of analysts had fallen by about 4.1% in the last three months.​

• In the last 30 days, three analysts negatively revised earnings estimates

RECOMMENDATIONS

• The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 13 "strong buy" or "buy," 6 "hold" and no "sell" or "strong sell." The average consensus recommendation for the biotechnology & medical research peer group is also "buy"

• Wall Street's median 12-month price target for Bio-Techne Corp is $65.00, about 15.9% above its last closing price of $54.64

This summary was machine generated from LSEG data August 6 at 02:30 p.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)